ctDNA, circulating tumor DNA; IO, immunotherapy
Predict recurrence with high sensitivity and specificity across the most common breast cancers
ctDNA, circulating tumor DNA; IO, immunotherapy
References: 1. Yang Y, Lu Y, Tan H, et al. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer. BMC Cancer. 2023;23(1):422. doi:10.1186/s12885-023-10863-w 2. Guardant Health data on file. October 19, 2023. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health data on file. Guardant Reveal on Infinity. Guardant Health, Inc. Redwood City, CA.
ctDNA, circulating tumor DNA; IO, immunotherapy
Predict recurrence with high sensitivity and specificity across the most common breast cancers
References: 1. Elliott MJ, Kim J, Dou A, et al. Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early breast cancer. ESMO Open. . 2025. 2. Ademuyiwa FO, Ma CX, Weilbaecher K, et al. Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in EarlyStage Triple-Negative Breast Cancer. Clin Cancer Res. 2025. 3. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res. 2024.
ctDNA, circulating tumor DNA; IO, immunotherapy